Clancy Clark to Pancreatic Neoplasms
This is a "connection" page, showing publications Clancy Clark has written about Pancreatic Neoplasms.
Connection Strength
1.540
-
Mogal H, Vermilion SA, Dodson R, Hsu FC, Howerton R, Shen P, Clark CJ. Modified Frailty Index Predicts Morbidity and Mortality After Pancreaticoduodenectomy. Ann Surg Oncol. 2017 Jun; 24(6):1714-1721.
Score: 0.527
-
Clark CJ, Graham RP, Arun JS, Harmsen WS, Reid-Lombardo KM. Clinical outcomes for anaplastic pancreatic cancer: a population-based study. J Am Coll Surg. 2012 Nov; 215(5):627-34.
Score: 0.394
-
Clark CJ, Traverso LW. Positive peritoneal lavage cytology is a predictor of worse survival in locally advanced pancreatic cancer. Am J Surg. 2010 May; 199(5):657-62.
Score: 0.332
-
Enomoto LM, Fenstermaker J, Desnoyers RJ, Pasche BC, Blackstock AW, Howerton RM, Clark CJ, Levine EA, Shen P. Oncology Navigation Decreases Time to Treatment in Patients with Pancreatic Malignancy. Ann Surg Oncol. 2019 May; 26(5):1512-1518.
Score: 0.152
-
Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D'Agostino R, Topaloglu U, Boteju LW, Boteju AR, Shorr R, Zachar Z, Bingham PM, Ahmed T, Crane S, Shah R, Migliano JJ, Pardee TS, Miller L, Hawkins G, Jin G, Zhang W, Pasche B. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncol. 2017 06; 18(6):770-778.
Score: 0.135